Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Equivalents (2019 - 2025)

Silence Therapeutics' Cash & Equivalents history spans 7 years, with the latest figure at $85.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 29.86% year-over-year to $85.1 million; the TTM value through Dec 2025 reached $85.1 million, down 29.86%, while the annual FY2025 figure was $85.1 million, 29.86% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $85.1 million at Silence Therapeutics, up from $82.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $121.3 million in Q4 2024 and bottomed at $41.7 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $75.4 million (2023), against an average of $76.5 million.
  • The largest annual shift saw Cash & Equivalents surged 173.5% in 2021 before it plummeted 50.32% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $99.1 million in 2021, then tumbled by 50.32% to $49.2 million in 2022, then skyrocketed by 39.68% to $68.8 million in 2023, then surged by 76.38% to $121.3 million in 2024, then decreased by 29.86% to $85.1 million in 2025.
  • Per Business Quant, the three most recent readings for SLN's Cash & Equivalents are $85.1 million (Q4 2025), $82.0 million (Q3 2025), and $41.7 million (Q2 2025).